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Background: Adherence to protease inhibitor-containing antiretroviral therapy is 
crucial, but difficult to measure. 
Objective: To compare and combine various methods of measuring adherence to 
the strict protease inhibitor-containing regimens. 
Methods: The following methods were used: medication event monitoring system 
(MEMS) caps (electronic monitoring), therapeutic drug monitoring, pill count, phar-
macy refill data, questionnaires, diaries (for registration of food patterns and special 
events related to the use of MEMS), adherence assessment by the physician and 
clinical nurse specialist, and in-depth interviews. In addition, ultrasensitive viral load 
and resistance testing was performed. 
Results: Twenty-eight patients were included; data could be evaluated in 26. Ac-
cording to MEMS data, 25% of the patients took fewer than 95% of all doses, and two 
thirds of the patients took fewer than 95% of the doses on time. Only 43% of the 
patients showed good adherence with food restrictions. Methods that showed signifi-
cant correlations with MEMS results were patients' self-reported adherence; therapeu-
tic drug monitoring, indicating plasma levels outside predefined ranges; and estimation 
of adherence by a clinical nurse specialist, especially by in-depth interview. 
Conclusion: Diary-corrected MEMS data gave a detailed insight into patients' 
adherence patterns. Patients' self-report and therapeutic drug monitoring were signifi-
cantly correlated with the MEMS data, and the clinical nurse specialist may also play 
a role in identifying patients who are imperfectly adherent. 
Key Words: Adherence-Electronic monitoring-HIV protease inhibitors-
Nurse-Plasma concentrations. 
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Although protease inhibitor-containing antiretroviral 
therapy has dramatically improved the outcomes for 
HIV-infected patients, suboptimal adherence to these 
complex regimens decreases the likelihood of suppress-
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ing viral replication and increases the likelihood of 
developing resistance (1-15). High adherence seems 
necessary (1,8,12,14), which means ingestion of the 
correct number of pills at the right time according to 
the prescribed food requirements. Adherence is further 
complicated by adverse events and factors such as 
stigmatization (16-19). 
lands; e-mail: p.hugen@klinfarm.azn.nl · 
Manuscript received August 30, 2001; accepted February 20, 2002. 
Financial support for this study was given by Abbott, GlaxoWell-
come, Merck Sharp & Dohme, and Roche. 
324 
Whereas the virologic implications of suboptimal ad-
herence are becoming increasingly clear, it is not yet 
apparent how adherence to these stringent regimens can 
best be measured. One problem in studying adherence is 
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the lack of a gold standard (20-22). Thus far, self-report 
has predominantly been used (5,6,8, 10,13,23-27). Re-
cently, a few studies using electronic monitoring have 
been presented (1,28-30). The medication event moni-
toring system (MEMS) records the opening and closing 
of a medication vial and thereby provides more detailed 
information. Nevertheless, it is still an indirect method 
because it does not measure drug ingestion. A direct, 
objective measure of ingestion of a drug is its plasma 
concentration (20,31), although it only gives short-time 
information. Adherence with food requirements can be 
measured with a diary or other kinds of self-report. 
The objective of our study was to combine several 
adherence-measuring methods to compare the informa-
tion provided by these various methods. We aimed to 
find a set of methods that enables adherence monitoring 
of all relevant aspects of protease inhibitor-containing 
antiretroviral therapy. With the availability of tools to 
reliably monitor adherence, an important step toward de-
veloping effective interventions that improve adherence 
can be made. 
MATERIALS AND METHODS 
Patients 
Two groups of outpatients were included in this study: I) patients 
who were starting antiretroviral combination therapy including one or 
more protease inhibitors (naives) and 2) patients who were already 
using protease inhibitor-containing combination therapy for more than 
48 weeks and who had an undetectable viral load (i.e., <400 or 500 
copies/mL at the previous two measurements before start of the study; 
non-naives). In this descriptive study, the patient sample is a conve-
nience sample, i.e., patient numbers were based on the availability of 
suitable patients in the two centers that participated, the University 
Medical Centre, Nijmegen and the Rijnstate Hospital, Arnhem. The 
goal was to include 20 naive and 20 non-naive patients, equally dis-
tributed over the two centers. 
Patients had to be between 18 and 65 years of age and able to read 
and speak Dutch. During follow-up evaluation, patients continued their 
original medication regimen, although changes according to standard of 
care were allowed. Patients were monitored for 24 weeks during which 
three (for non-naives) or four (for naives) visits were planned, analo-
gous to regular visits. Sociodemographic and other patient character-
istics were registered during the first of these visits. If patients did not 
want to participate, the reasons for refusal, according to the patient and 
the nurse, were marked. 
All participants signed written informed consent, and the study was 
approved by the local Ethics Committees of both study centers. 
Medication Event Monitoring System 
In this study, the MEMS was used, more specifically the eDEMs 
Track caps (Aardex, Zug, Switzerland), in combination with 200-mL 
pill bottles. Medication dosing times were retrieved from the cap and 
analyzed by the Powerview program (Aardex, Zug, Switzerland). 
For our study, we used an intermediate version of Powerview that 
enabled us to insert and delete events to correct the MEMS data. These 
corrections were necessary because the bottle was also opened during 
study visits and for refills, although generally no medication was taken 
at those times. In these cases, data were corrected based on notes from 
the diary or on the study visit forms. 
Patients who used a medication cassette to organize their protease 
inhibitor ingestions and who were not willing to stop this practice 
during the study were excluded, although patients were allowed to take 
their medication out of the MEMS bottle before the actual ingestion 
time, if only sporadically. MEMS data were also corrected for these 
occurrences. 
The MEMS caps were supplied only for the protease inhibitors. 
During the study, regular prescriptions were used. Medication was 
supplied by the patient's local pharmacy and registered according to the 
regular method at that particular pharmacy. Patients performed the 
refills themselves. They were explicitly instructed only to use the 
MEMS bottle and to make notes of deviations. Also, they were told to 
ingest the medication directly after taking it from the bottle. Patients 
were aware of the function of the MEMS bottle. 
Parameters extracted from the Powerview report were percentage of 
prescribed medication taken, percentage of medication taken on sched-
ule (i.e., within 1 hour before or after the scheduled time), and per-
centage of days on which the correct number of doses was taken. The 
calendar plot (overview of number of doses taken each day) and chro-
nology plot (schematic report of dose-timing) were also visually 
inspected. 
Questionnaires 
Questionnaires were completed by patients at every planned study 
visit, i.e., at baseline and at 12- and 24-week follow-up evaluations. For 
naive patients, an extra questionnaire was supplied at week 4, and an 
adjusted questionnaire was given at baseline. The questions were com-
pleted without supervision of the physician or nurse. 
The names of antiretroviral agents used, with dosing regimen and 
food restrictions, were noted on the questionnaire. In addition, patients 
assessed their adherence based on ingestion of the correct number of 
doses and pills, the timing of ingestion, and adherence with food re-
strictions (visual analog scale from 1 [not precise] to 10 [very precise]). 
After completion, the questionnaires were placed in a sealed enve-
lope and sent directly to the investigator. The mean estimate over the 
various visits was calculated. 
Diaries 
Patients were given six 3 I-day diaries. With respect to measuring 
adherence, the diary contained the following items: timing and com-
position of meals (scale 1-5 for amount and fat content, examples were 
given in the instructions) and specific issues related to MEMS use 
(participants had to mark refills, device use, and other unscheduled 
openings). The use of diaries in this study was not intended for mea-
suring adherence regarding ingestion. Patients were asked to update 
their diaries four times a day. 
Analysis of adherence with food requirements was done by relating 
what the patient reported to consider as food requirements in the ques-
tionnaire to the data concerning food in the diary and the MEMS 
ingestion times. We looked at general food patterns over the entire 
study period and performed a detailed analysis of five randomly chosen 
days per patient. The interval between medication and food intake and 
the composition with respect to portion and fat content were compared 
with the requirements (indinavir, minor or no food intake 2 hours 
before and I hour after ingestion of medication; other regimens, intake 
of medication within 2 hours of food intake). Thus, patients were 
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categorized into three groups: ( 1) good (no deviation), (2) moderate 
(minor deviations, irregularly), and (3) poor (frequent or major devia-
tions) compliance with food restrictions. 
Adherence Assessment by Treating Physician and 
Clinical Nurse Specialist 
At each visit, the treating physician and clinical nurse specialist 
assessed the adherence of the patient in the same way the patient had 
done in the questionnaire (based on ingestion of correct number of 
doses and pills, timing of ingestion, and adherence with food restric-
tions; visual analog scale from I [not precise] to 10 [very precise]). The 
mean estimate over the various visits was calculated. 
Plasma Drug Concentrations 
Plasma samples were drawn at each visit, including unplanned visits, 
to determine protease inhibitor concentrations. Two weeks after start of 
the follow-up period, an 8-hour pharmacokinetic profile was recorded. 
The samples were analyzed with a validated high-performance liquid 
chromatography (HPLC) method, with a lower limit of quantitation of 
.04 mg/L (32). Random plasma concentrations were compared with the 
expected concentration at the corresponding time after ingestion, i.e., 
the interval between dose intake and plasma sampling according to the 
patient. For a comparison with the individual curve, deviation from the 
expected concentrations was calculated by determining the median ab-
solute deviation from the expected ratio 1 (1 = equal to concentration 
after observed ingestion). For a comparison with population curves, 
predefined limits, known as concentration ratio limits (CORALS), were 
used. CORALS generally reflect plasma concentrations 2-3 times 
higher than reference population values after observed ingestion or 
lower than one third to one sixth of these population values. Concen-
trations outside these limits have been found to be predictive for non-
adherence (33). For each patient, the percentage of samples outside 
these limits was determined. 
Pill Count and Pharmacy Refill Data 
At each visit, patients were asked to bring their antiretroviral medi-
cation to the hospital for a pill count. The number of pills in the MEMS 
bottle and those in the unopened and opened bottles were counted and 
registered separately. 
On the second part of the pill count form, the prescriptions given at 
that particular visit were registered. By combining pill count and pre-
scription data, the percentage of doses taken of the protease inhibitor 
could be calculated. 
At the end of follow-up period, the pharmacy refill data for each 
patient were requested at the local pharmacy. Most pharmacy refill 
reports already include a calculation of the date on which the stock will 
be finished. From this refill report, the regularity of the refill pattern 
could be deduced. Pill count and refill data were combined to calculate 
the percentage of doses taken. The pill count at baseline reflected the 
initial stock; the one at the end of follow-up period, the final stock. The 
in-between refills reported by the local pharmacy reflected new stock. 
The following formula was used to calculate the percentage taken. 
(initial stock+ 
refilled amount) - final stock 
---------- X I 00 =%of pills taken 
number of pills per day * 
number of days in follow-up 
In-Depth Interview 
An in-depth interview by the clinical nurse specialist was held with 
a subgroup of patients at the end of follow-up period. Patients had to 
give consent for the interview at the start of the study; patients who 
either refused or stopped prematurely were replaced. 
The interview was semi-structured: a list of questions was supplied 
to give direction to the conversation. The interviews were recorded on 
tape, and the patients were told that no one besides the investigators 
would hear the interview and that the interview would be processed 
anonymously. 
After transposition, statements regarding the patients' adherence 
were extracted by two researchers. By combining these statements, 
patients' adherence was categorized as 1) good (no deviations in in-
gestion, timing, or food requirements reported), 2) moderate (minor 
deviations reported), or 3) poor (patient admitting skipping doses, ir-
regular drug intake, or deviations from food requirements). 
Viral Load and Resistance Analysis 
In addition to standard viral load measurements (cut off, 400 or 500 
copies/mL), ultrasensitive measurements (cut-off, 25 copies/mL; Ul-
trasensitive HIV-I Cobas Amplicor Monitor Assay, Roche Diagnos-
tics, Pleasantin, CA, U.S.A.) were performed at baseline and at the end 
of follow-up period. If the viral load at the end of follow-up period was 
> 1000 copies/mL, genotypic resistance analysis was performed using 
an automated sequencer (ABI 377, PE Biosystems, Foster City, 
CA, U.S.A.) and Big-Dye-terminator chemistry (PE Biosystems). 
Population sequencing of the entire protease gene and of the RT 
gene from amino acid 1-300 was performed using polymerase chain 
reaction (PCR) amplified genome fragments derived from plasma virus 
RNA (34). 
Statistics 
Statistics were performed with SPSS for Windows (v. 9.0, SPSS Inc., 
Chicago, IL, U.S.A.). To compare the various methods with MEMS 
data, nonparametric Spearman correlation coefficients (r) were calcu-
lated with their corresponding levels of significance. Spearman r values 
of < .35 were regarded insufficient, whereas r values of 0.6--0. 7 were 
high enough to consider the method comparable with MEMS data. p < 
.05 was regarded as significant. To compare a combination of methods 
with MEMS, categoric data of the specific methods were multiplied 
and then Spearman correlation coefficients were calculated again. Cat-
egorization of the data was done to increase the sensitivity of the 
methods to discriminate poor adherence from moderate or good adher-
ence, although some methods did not result in numerical data. The 
categories were based on the literature or extracted from the data. The 
following cut-off points were used: MEMS % taken and % of days 
correct number of doses taken, I (good adherence): 2:95%, 2 (moder-
ate): 95%-90%, 3 (poor): <90%; MEMS % on schedule, >90%, 90%-
80%, and <80%; self-reported adherence/physician and nurse estimate, 
>9.0, 9.0-8.0, :S:8.0; pill count/refill data, I: 2:95%, 2: 95%-90%, 3: 
<90%; plasma concentrations, I: 0% plasma concentrations outside 
CORALS, 3: >0%; in-depth interviews, categorized based on the state-
ments of the patients concerning their own adherence. 
RESULTS 
Patients 
Twenty-eight patients were included in the study: 21 
non-naive, 7 naive. Non-naive patients had a median 
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duration of antiretroviral therapy use of 2.5 years (inter-
quartile range [IQR], 2.0-3.3). Thirteen patients used a 
twice-daily regimen; the other 15 used a thrice-daily dos-
ing frequency. Indinavir taken alone and the combination 
of ritonavir + saquinavir were the most frequently used 
protease inhibitors (12 and 10 patients, respectively). All 
patients but 1 were male, and all but 1 white; most (19 of 
28) were homosexual. 
Twenty-six patients completed follow-up week 12, 
and 24 completed follow-up week 24. Four of the 28 
patients stopped prematurely (before follow-up week 24) 
because of protease inhibitor toxicity (1 naive, 2 non-
naive patients) or patient request (I non-naive patient). 
Two of these patients stopped therapy before follow-up 
week 4 and were not included in the analyses. 
Medication Event Monitoring System 
According to the corrected MEMS reports ( corrected 
for notes in diary, during visits, etc.), the median per-
centage of prescribed doses taken (% taken) was 98.9% 
(range, 10.1 %-102.0% ); the percentage of days on which 
the correct number of doses was taken (% correct days) 
was 94.6% (range, 4.1 %-99.5% ), and the percentage of 
doses taken on schedule (% on schedule, within 1 hour 
before or after the scheduled time) was 91.1 % (range, 
6.4%-100.3% ). Twenty-five percent of the patients took 
fewer than 95% of all doses; 50% of the patients took the 
correct number of doses fewer than 95% of the days, and 
two thirds of the patients took fewer than 95% of the 
doses on time (Fig. l). Figure 2 shows an example of 
perfect and imperfect compliance as depicted in MEMS 
chronology plots. 
Questionnaires 
From the questionnaire, the patient's dosing regimen 
was extracted and used to analyze the MEMS data. In 4 
cases (15%), food restrictions, according to the patients, 
were different than advised. Median patients' self-
reported adherence (average of several measurements 
per patient) was 8.6 on a scale from 1 to l 0 (IQR, 8.0-
9.3). The lowest mark given was 5.7. 
Diaries 
Of the 26 patients, l patient did not take enough doses 
to analyze his accompanying food pattern, 1 did not suf-
ficiently complete the food part of the diary, and 3 pa-
tients reported not to be restricted to food requirements. 
Of the other 21 patients, 9 (43%) complied well with the 
food restrictions, 4 (19%) complied moderately, and 8 
% taken 
<70% 
90-95 
% days with correct nr of doses 
<70% 70-80%1) 
>95% 
80-90% 
90-95 
% on time 
<70% 
~95% 
70-80o/:• 
80-90 1/o 90-95 
FIG. 1. Distribution of adherence over the study population. 
Twenty-seven percent of the patients took fewer than 95% of all 
doses; 54% took the correct number of doses for fewer than 95% 
of the days, and 69% took fewer than 95% of the doses on time 
(within 1 hour before or after the scheduled time). 
(38%) poorly. Of the evaluative patients, 11 had to take 
their medication on (nearly) empty stomach, whereas 10 
patients had to take their medication with (fat) food. 
Adherence with food restrictions in the first group was 
comparable with that in the second group (p = .495, 
Mann-Whitney U test). 
Adherence Assessment by Treating Physician and 
Clinical Nurse Specialist 
The median adherence as reported by the nurse was 
8.8 (IQR, 7.9-9.3) and by the physician 9.0 (IQR, 8.3-
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FIG. 2. Chronology plot and missing doses of 2 patients on a twice-daily schedule. The upper two panels are from a patient with perfect 
adherence (taken, 101 %; on schedule, 100%; days with correct number of doses, 99%). The lower two panels are from a patient with 
imperfect adherence (taken, 92%; on schedule, 77%; days with correct number of doses, 81 %). Time is depicted on the Y axis; the date, 
on the X axis. Manually inserted and excluded events are based on notes in the diaries and visit forms. The grey horizontal bars represen1 
the permitted time interval of the scheduled doses (± 1 hour). 
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9.6). The nurses did not give anyone a score below 6.0 
compared with the 7.1 low score given by the physicians. 
Plasma Drug Concentrations 
The mean number of plasma samples per patient 
was 5.5 (SD, 1.9). The number of evaluative samples 
was 143. 
Deviations in protease inhibitor concentrations com-
pared with intrapatient reference values recorded under 
supervised ingestion ranged from 10% to 167%, with a 
median deviation of 36%. Using CORALS, the percent-
age of abnormal plasma concentrations among patients 
ranged from 0% to 88% (median, 0%), with 6 patients 
(23%) having one or more abnormal plasma concentra-
tions. Two patients (8%) had one or more plasma con-
centrations below the lower limit of quantitation. 
Pill Count and Pharmacy Refill Data 
When pill count and pharmacy refill data were com-
bined, the median percentage of pills taken was 100% 
(range, 71 %-132% ). Thirty percent of the patients were 
regarded as overadherent. In a small pilot study of 5 
patients, a detailed analysis of the pill count and phar-
macy refill data was performed. Several problems with 
these methods were encountered. First, there were strong 
indications that the pill count data had been manipulated, 
as has also been found by others, by the patient with the 
poorest compliance according to the MEMS data (35). 
For example, MEMS openings were recorded shortly be-
fore visits, although no medication had been ingested at 
that time as was shown by undetectable plasma levels. 
Also, prescriptions were refilled shortly before visits, 
although the pill count forms indicated that this patient 
had had insufficient stock much earlier. Most likely the 
,tock that the patient was assumed to have at home was 
brought to the hospital, and the excess was left at home. 
:-..revertheless, it was difficult to determine the patient's 
1ctual behavior from the pill count and refill data, and the 
:ombination provides an enormous overestimation of the 
1dherence according to MEMS (101 [pill count/refill] vs. 
LO% [MEMS] taken). 
Problems encountered with other patients from the pi-
ot study were mixing of stocks among partners who 
1sed the same medication, inaccurate reporting of pre-
;criptions by nurses, patients having old prescriptions at 
1ome, patients forgetting to bring the medication to the 
1ospital, either purposely or accidentally. 
In-Depth Interviews 
The clinical nurse specialist held an in-depth interview 
;vith 14 of the 26 patients. One patient (7%) was catego-
rized as having poor compliance; 6 (43%) were catego-
rized as having moderate compliance, and the other 7 
(50%) as having good compliance. 
Correlation Between Different Methods 
Table 1 shows all individual results as numeric values, 
if available, and categorized as well, as described in the 
Methods section. Table 2 lists the Spearman correlation 
coefficients (p) of the MEMS data compared with the 
other methods. 
According to the plasma concentration data obtained 
from the CORALS listed in the tables, protease inhibitor 
plasma concentrations deviated more from intrapatient 
reference values, recorded under supervised ingestion, in 
patients who were less adherent according to the MEMS 
data (% taken: Spearman p, -.426; p < .05; % on time: 
Spearman p, -.527; p < .01). In addition to assessing 
adherence in itself, plasma concentrations added relevant 
information to MEMS in cases where the MEMS data 
reported ingestion but plasma levels were undetectable 
or vice versa, and they were an objective check for the 
accuracy of the MEMS data. 
After adherence with food had been categorized as (1) 
good (no violation of food restrictions), (2) moderate 
(minor violations), or (3) poor (repetitive and more se-
rious violations), the correlation with the categorized 
MEMS data was as follows: MEMS % taken: Spearman 
p = .559, p < .01; MEMS % on time: Spearman p = 
.673, p < .01. 
Methods that showed relatively high and significant 
correlations with the MEMS results were patients' self-
reported estimate of adherence in the anonymous ques-
tionnaire (p, .73; p < .001), plasma levels outside pre-
defined ranges (p, .77; p < .001), and, to a lesser extent, 
estimation of adherence by the clinical nurse specialist 
(p, .57; p < .01). A combination of these methods did not 
increase the relation with the MEMS results (p, .57; p < 
.01, to p, .72; p < .001). The physician's estimate of 
adherence correlated less well (p, .43; p < .05), and the 
combination of pill count and pharmacy refill data only 
correlated significantly with the MEMS data when 
overadherence was judged as poor adherence (catego-
rized on the basis of the absolute deviation from 100%; 
p, .43; p < .05). In a subgroup, in-depth interviews with 
the clinical nurse specialist resulted in a high correlation 
with the MEMS results (p, .78; p < .01). 
Acceptance of Study Methods 
The following comments on the study methods were 
made: the MEMS vial was too large to handle (200-mL 
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TABLE 1. Comparison of adherence measured by various methods (adherence category numbers in parentheses) 
Non-
Protease naive/ MEMS, MEMS, MEMS, Food Questionnaire Physician HIV nurse Pill count Plasma 
Patient inhibitor BIDfTID naive % taken % days % on time (diary) (self-report) estimate estimate +refills(%) level" Interview 
I" !DY 3 NN 97 (I) 87 (3) 80 (2) 2 9.0 (2) 10.0 (I) 9.0 (2) ND" 0 (I) ND 
2 !DY 3 NN 100 (I) 99 (I) 92 (I) I 7.0 (3) 9.0 (2) 8.6 (2) 100 (I) 0 (l) ND 
3 NFV + SQV 2 NN 86 (3) 74 (3) 78 (3) 3 8.0 (3) 8.7 (2) 8.3 (2) 86 (3) 50 (3) ND 
4"·" NFV 2 NN 94 (2) 87 (3) 90 (2) 9.0 (2) 8.5 (2) 8.5 (2) ND" 0(1) ND 
5 RTV + SQV 2 NN 99 (I) 97 (I) 95 (I) 9.3 (I) 10.0 (I) 9.3 (I) 98 (I) 0 (I) ND 
6 !DY 3 NN 98 (I) 94 (2) 93 (I) 8.3 (2) 10.0 (I) 9.3 (I) 10091) 0 (I) 
7c RTV + SQV 2 NN 99 (I) 99 (I) 99 (I) 9.3 (I) 9.0 (2) 10.0 (I) 99 (I) 0 (I) 
3c RTV + SQV 2 NN 10 (3) 4 (3) 6 (3) 8.0 (3) 7.9 (3) 7.7 (3) IOI (I) 88 (3) ND 
9 RTV + SQV 2 NN 88 (3) 76 (3) 67 (3)_ 3 7.7 (3) 8.5 (2) 8.0 (3) 126 (]) 50 (3) 3 
10 RTV + SQV 2 NN 100 (I) 95 (I) 93 (I) 3 9.0 (2) 8.3 (2) 8.2 (2) 100 (]) 25 (3) I 
II !DY 3 NN 99 (I) 88 (3) 83 (2) I 8.0 (3) 8.3 (2) 8.8 (2) 71 (3) 0 (I) ND 
12 !DY 3 NN 98 (]) 95 (I) 78 (3) 3 5.7 (3) 8.8 (2) 7.4 (3) 98 (I) 0 (I) 2 
13 !DY 3 NN 97 (I) 84 (3) 81 (2) 2 8.0 (3) 7.6 (3) 9.3 (I) IO0 (I) 0(1) 2 
14 !DY 3 NN 99 (I) 98 (I) 87 (2) 2 9.0(2) 9.8 (I) 9.4 (I) NDJ 0 (I) 2 
15c RTV + SQV 2 NN 83 (3) 71 (3) 31 (3) 7.7 (3) 7.1 (3) 6.0 (3) 121 (I) 14 (3) NDb 
16 SQV 3 NN 102 (I) 91 (2) 69 (3) 3 9.0 (2) 9.1 (1) 8.7 (2) 93 (2) 0(1) ND 
17 RTV + SQV 2 NN 101 (]) 98 (I) IO0(l) 2 10.0 (I) 10.0 (I) 9.5 (I) 87 (3) 0 (I) I 
18c RTV + SQV 2 NN 99 (I) 97 (I) 98 (I) I0.0 (I) 9.2 (I) 9.3(1) IOI (I) 0 (I) ND 
19 !DY 3 NN 100 (I) 97 (]) 97 (I) I 10.0 (1) 7.7 (3) 7.7 (3) IOI (I) 0 (I) I 
20 !DY 3 NN 99 (I) 97 (I) 92 (I) 3 10.0 (I) 9.3 (I) 10.0 (I) 100 (I) 0 (I) 2 
Stopped 
21 RTV + !DY 2 NN <4 weeks X X X X X X X X X 
22 !DY 3 NA 100 (I) 97 (I) 97 (]) I 9.8 (I) 9.6 (]) 9.3 (I) 95 (I) 0 (I) 2 
23 NFV 2 NA 99 (I) 98 (I) 96 (]) I 8.5 (2) 9.1 (I) 9.8 (I) 132 (I) 0 (I) I 
24 !DY 3 NA 94(2) 81 (3) 90 (2) 3 8.8 (2) 9.3 (I) 9.5 (I) 80 (3) 0 (I) 2 
25 RTV + SQV 2 NA 100 (I) 100 (]) 93 (I) 8.8 (2) 8.2 (2) 7.5 (3) 126 (]) 0 (I) ND 
26 RTV + SQV 2 NA 99 (I) 98 (]) 97 (I) I 9.0 (2) 9.6 (I) 8.8 (2) 100(1) 0 (I) I 
27 NFV 2 NA 88 (3) 73 (3) 62 (3) 3 7.7 (3) 8.5 (2) 7.2 (3) 92 (2) 50 (3) NDb 
Stopped 
28 !DY 3 NA <4 weeks X X X X X X X X X 
MEMS % taken: percentage of doses taken according to MEMS. MEMS % days: percentage of days on which the correct number of doses was taken. MEMS % or 
time: percentage of doses taken within 1 hour before or after the scheduled ingestion time. 
Adherence categories: I = good adherence; 2 = moderate adherence; 3 = poor adherence. 
" Patient I stopped medication between 12 and 24 weeks of follow-up observation; patient 4 withdrew consent at 12 weeks of follow-up observation. 
"Patient I 5 eventually refused cooperation, patient 27 was too depressed at the time of the interview. 
,.· Patients 4, 7, and 18 reported to have no food restrictions, patient 8 had not enough ingestions to enable analysis of his food pattern, and the diary registration of patien 
15 was too poor to enable analysis of his food pattern. 
"No refill data available. 
"Percentage of plasma concentration outside CORALS (concentration ratio limits). 
!DY, indinavir; NFV, nelfinavir; RTR, ritonavir; SQV, saquinavir; NN, non-naive; NA, naive; ND, not done. 
bottles were used because of the large number of pills); 
having only one vial was inconvenient, and not being 
able to use a medication cassette was problematic. Keep-
ing the diary was problematic, especially adding entries 
four times a day. Specific items with respect to MEMS 
were scored well, but items that had to be scored more 
often, such as the amount and fat content of food, were 
more difficult for some patients. As a result, several pa-
tients filled in all items once daily. The pill count was 
accepted well, although in practice, patients sometimes 
did not bring their pills with them. 
Viral Load and Resistance Analysis 
For 23 of the 26 patients, ultrasensitive viral load data 
(cut off 25 copies/mL) were available at the end of fol-
low-up period. In 2 patients, the viral load was detect-
able. One of these patients (non-naive, number 14 in the 
table) had 1290 copies/mL. According to MEMS, this 
patient took 99% of the doses, and 87% were taken or 
time. Deviations in timing were small but occurred regu 
larly. However, the viral load increase may also be ex 
plained by a relatively low indinavir exposure, whicl 
was seen even after observed ingestion. Resistanct 
analysis showed resistance to zidovudine and abacavir 
although zidovudine was only used before the study. 
A second non-naive patient (number 8 in the table 
had 3635 copies/mL; this patient had the poorest adher 
ence (10% taken according to MEMS and probably eve1 
less according to undetectable plasma concentrations af 
ter MEMS opening). This patient's virus was resistan 
for zidovudine, abacavir, and lamivudine but not for pro 
tease inhibitors. He had used zidovudine and lamivudini 
during the study and long before. The viral loads of thi 
other 21 patients were undetectable (<25 copies/mL) 
although 5 patients (3 non-naive and 2 naive) had take1 
fewer than 95% of their doses (the lowest % taken wa 
83%) and 8 (7 non-naive, 1 naive) had taken fewer tha1 
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TABLE 2. Correlations between MEMS results and other methods to measure adherence 
MEMS (% taken) MEMS (% taken on time) 
Spearman Spearman 
Method rho numeric Ordinal rho numeric ordinal 
Questionnaire (self-report) 0.552" 0.538c 0.721" 0.731" 
Plasma concentrations <> CORALS -0.568c 0.768" -0.593c 0.543c 
Nurse estimate 0.287 0.472b 0.567" 0.530c 
Physician estimate 0.273 0.426,, 0.429b 0.387 
Pill count/refill data 
Percentage -0.074 0.284 0.027 0.382 
Deviation from 100% -0.146 0.414 -0.229 0.430b 
In-depth interviewa X 0.550* X 0.778c 
Combination of methods 
Q X PIX N X 0.618c X 0.684" 
Q X PI X 0.642" X 0.721" 
QxN X 0.569c X 0.705" 
PlxN X 0.610b X 0.586" 
For the ordinal results the categorization as listed in Table is used. Additionally, the pill 
count/refill data are calculated as the absolute deviation from I 00% and categorized by dividing the 
deviations into 3 equal groups. 
"In-depth interviews were held in 14 of the 26 patients. CORALS, concentration ratio limits; Q, 
questionnaire; PI, plasma concentrations; N, nurse estimate. Combination of methods was calculated 
by multiplying the category numbers. 
b p < .05. 
C p < .01. 
d p < .001. 
90% of their doses on time (31 %-83%) according to 
MEMS. 
DISCUSSION 
In this study, diary-corrected MEMS data gave a de-
tailed and accurate insight into adherence patterns of 
HIV-infected patients using protease inhibitor-
containing antiretroviral therapy. Patients' self-report 
and therapeutic drug monitoring were significantly and 
highly correlated with adherence according to MEMS, as 
was the case for the in-depth interviews held by the 
clinical nurse specialist. 
Medication Event Monitoring System 
The MEMS caps were only supplied for the protease 
inhibitors because this class of medication has the most 
stringent requirements with respect to dose frequency, 
timing, and food intake. Nucleoside reverse transcriptase 
inhibitors are less vulnerable, and although non-
nucleoside analogs are at high risk for development of 
resistance, their long elimination half-lives make them 
less prone to nonadherence. 
Because of the different appearance of the MEMS 
bottle and cap and the refill necessity at home, telling the 
patients about the function of the MEMS caps could not 
be avoided. For this reason, and others, a follow-up pe-
riod of 24 weeks was chosen: we assumed it to be un-
likely for patients to mimic perfect adherence for a long 
period (36,37). 
By using MEMS caps, various patterns of adherence 
were seen among different patients. Specific problems 
such as missing afternoon doses, variation in the timing 
of the bedtime dose, and changed timing during week-
ends were seen. Such detailed information will enable a 
targeted intervention to improve adherence (38). 
Self-Report and In-Depth Interview 
Self-report is often regarded as a method that overes-
timates adherence ( 13,29,30). However, an estimate of 
poor adherence by a patient should be regarded seriously 
(21); several studies have demonstrated an association 
between self-report and viral outcome (10, 12,23,29). 
When patients were asked anonymously about their 
adherence in our study, their estimate corresponded rela-
tively well with the results from the MEMS caps. Par-
ticularly, patients who repeatedly gave themselves an 8 
or lower on a visual analog scale from 1 to 10 appeared 
to be imperfectly adherent, which proves that it is useful 
to ask patients about their adherence. This request may 
be done in writing by a third party, i.e., not by the treat-
ing physician, but, for example, by a pharmacist. 
The physician too often gave a wrong estimate of the 
patient's adherence to turn his or her judgment into a 
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useful method, as has been shown before (1,28). The 
nurse was better able to judge the patient's adherence. 
When the nurse held an in-depth interview with the pa-
tient and remarks with respect to adherence were ex-
tracted to categorize the patients' adherence, a rather 
strong correlation with adherence according to MEMS 
was found. This finding could mean that the approach-
ability of and the close relationship with the nurse, as 
mentioned by patients in their interviews, reveals de-
tailed and reliable information on adherence. 
Therapeutic Drug Monitoring 
When looking at plasma concentrations drawn after 
unobserved ingestion, the patients with larger deviations 
from their individual pharmacokinetic profile after ob-
served ingestion appeared to be less adherent according 
to MEMS. Additionally, we saw a strong relation be-
tween having plasma concentrations outside predefined 
population concentration limits assessed after observed 
ingestion (i.e., CORALS) (33) and nonadherence, espe-
cially with respect to the number of doses taken. Five of 
the 6 patients with one or more plasma concentrations 
outside the CORALS took less than 90% of their medi-
cation according to MEMS, and thus were detected by 
repeated therapeutic drug monitoring. These 5 patients 
were the only ones who were categorized as having poor 
compliance (MEMS, <90% taken, category 3). 
A disadvantage of plasma sampling is that patients 
could mimic perfect adherence by taking doses shortly 
before a visit (37 ,39). Although this still may cause ab-
normal plasma concentrations, for example, because no 
autoinduction has occurred during the days of nonadher-
ence, dose-timing is wrong, or extra doses are taken to 
compensate for missed doses (40), there is a chance that 
nonadherence will not be detected. Nevertheless, the re-
sults of the current study show that when patients knew 
that their plasma concentrations were determined, devi-
ating plasma concentrations were found that correlated 
with imperfect adherence according to MEMS. This re-
sult agrees with the observation that the MEMS reports 
did not show an improvement in adherence shortly be-
fore study visits. The absence of this "toothbrush effect" 
has been described before (36). 
Pharmacy Refill Data and Pill Count 
Only a rough estimation of the refill pattern could be 
extracted from the pharmacy refill data (3). Most patients 
in this study were in the non-naive group and may have 
had a stock of pills at home. The number of pills in this 
stock is unknown if no pill count is performed, and thus 
the exact situation cannot be assessed with refill data 
alone (35). Only a combination of pill count and phar-
macy refill data could give an estimation of adherence in 
this study. Nevertheless, even by combining pill count 
and pharmacy refill data, a percentage of adherence 
could be calculated that may appear rather good, but that, 
when reviewing the stocks at several time points, shows 
overuse or underuse, indicating that the overall calcula-
tion is actually inaccurate. This finding agrees with the 
poor correlation between adherence according to MEMS 
and adherence according to pill count and refill data in 
the current study and with the limitations of the methods 
recognized by others (3,4,20,31,40,41). 
Diaries 
Analysis of adherence with food restrictions registered 
in the diaries was based on the food requirements re-
ported by the patient in the questionnaire because in-
structions may have been incorrect. Ftorri the analysis of 
food patterns in the diaries, it became clear that violation 
of the requirements occurred for the drugs that had to be 
taken with food (fat) and those that had to be taken on a 
nearly empty stomach. 
It was found that_ keeping a diary, especially when it 
has to be completed several times per day, is problematic 
for patients and therefore cannot be applied to larger 
patient groups. Monitoring adherence with food restric-
tions is difficult to perform. One approach is to have 
the clinical nurse specialist discuss this issue with the 
patient. 
Adherence Rate 
Our patient group may seem highly adherent com-
pared with the adherence rates found by others (1,3,13, 
29,36), but we suspect that 11 %-16% of the patients who 
refused to participate would have been nonadherent; in 
other words, we did not select an extremely adherent 
patient group. A more likely explanation for the rela-
tively high adherence may be found in the inclusion cri-
teria: only patients without communication problems 
were included, and in the majority of the participants, 
their therapy thus far had been effective-one of the 
causes of good efficacy may be good adherence. 
Viral Load 
From the viral load data in this study, it is noted that 
virologic failure occurred only in the patient with the 
poorest compliance during the 24-week study period. 
Other patients reached or kept undetectable viral loads, 
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even though adherence was sometimes lower than the 
threshold necessary for virologic suppression as sug-
gested by others (l,8,12,14). However, the viral load 
results from this study are only indicative because the 
study group is heterogeneous, with respect to duration of 
therapy, kind of pretreatment, and pretreatment viral 
load. The latter was not always known and may be im-
portant for the grade of adherence needed to reach and 
maintain viral suppression. Nevertheless, patients with 
lower adherence are at risk for virologic failure and pos-
sible development of virologic resistance (1-14), al-
though no thresholds can be determined from this study, 
and exact relations are not yet fully understood. 
In conclusion, the MEMS data give a detailed insight 
into patients' adherence patterns. Notes about special 
events occurring in relation to MEMS caps, such as visit 
openings, refills at home, or device use, should be used 
to correct the MEMS data to improve their accuracy ( 42). 
Therapeutic drug monitoring can be used as a direct mea-
sure to objectify the MEMS results, whereas plasma con-
centrations outside predefined limits are highly corre-
lated with the MEMS results and thus can be used to 
detect nonadherent patients. Another method that 
showed a highly significant correlation with the MEMS 
results was the patients' self-reported estimate of adher-
ence in an anonymous questionnaire and, to a lesser ex-
tent, the estimation of adherence by a clinical nurse spe-
cialist. In a random subgroup, in-depth interviews with 
the clinical nurse specialist resulted in a high correlation 
with the MEMS results, which could mean that by al-
lowing patients talk to a person they trust and who is 
easily accessible may help to reveal nonadherence. Thus, 
therapeutic drug monitoring, patients' self-report, and 
clinical nurse specialist assessment of adherence after an 
in-depth interview with the patient can be used to detect 
patients who have a problem with adherence, and MEMS 
can be used in problematic patient groups in whom in-
terventions are planned because MEMS give a real in-
sight into adherence patterns. In addition to MEMS, dia-
ries should be used, plasma concentrations should be 
measured, and patients should always be asked about 
their adherence, preferably by a clinical nurse specialist 
or a third party, such as a pharmacist. 
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